Most importantly, the depletion of CHD4 in MCF10A cells, a human mammary epithelial cell line that lacks tumorigenic potential, did not affect cell proliferation and migration in vitro, suggesting that CHD4 targeting has the potential to become a novel therapeutic strategy to impair BC progression (D'Alesio et al., 2016). The gene discussed is CHD4; the disease is breast cancer.